25 related articles for article (PubMed ID: 17922333)
1. Exercise training reduces systemic inflammation and improves general health status in female migraineurs: a randomised controlled trail.
Pairo Z; Parnow A; Sari Aslani P; Mohammadi P; Mirzaeei S; Mohr M
Eur J Appl Physiol; 2024 May; 124(5):1397-1408. PubMed ID: 38043087
[TBL] [Abstract][Full Text] [Related]
2. ProMMP-2: TIMP-1 complexes identified in plasma of healthy individuals.
Zucker S; Schmidt CE; Dufour A; Kaplan RC; Park HI; Jiang W
Connect Tissue Res; 2009; 50(4):223-31. PubMed ID: 19637058
[TBL] [Abstract][Full Text] [Related]
3. A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus.
Derosa G; Maffioli P
Vasc Health Risk Manag; 2016; 12():415-419. PubMed ID: 27877049
[TBL] [Abstract][Full Text] [Related]
4. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
Derosa G; Mugellini A; Pesce RM; D'Angelo A; Maffioli P
BMC Cardiovasc Disord; 2016 Apr; 16():66. PubMed ID: 27068332
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study.
Peeters SA; Engelen L; Buijs J; Chaturvedi N; Fuller JH; Schalkwijk CG; Stehouwer CD;
Cardiovasc Diabetol; 2015 Mar; 14():31. PubMed ID: 25848912
[TBL] [Abstract][Full Text] [Related]
6. Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity.
Belo VA; Luizon MR; Carneiro PC; Gomes VA; Lacchini R; Lanna CM; Souza-Costa DC; Tanus-Santos JE
Mol Biol Rep; 2013 Mar; 40(3):2697-704. PubMed ID: 23242659
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study.
Knudsen EC; Seljeflot I; Michael A; Eritsland J; Mangschau A; Müller C; Arnesen H; Andersen GØ
Cardiovasc Diabetol; 2010 Sep; 9():47. PubMed ID: 20809989
[TBL] [Abstract][Full Text] [Related]
8. Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease.
Furenes EB; Seljeflot I; Solheim S; Hjerkinn EM; Arnesen H
Scand J Clin Lab Invest; 2008; 68(3):177-84. PubMed ID: 17934973
[TBL] [Abstract][Full Text] [Related]
9. [Involvement of matrix metalloproteinases in acute coronary syndrome (ACS)].
Pérez-Hernández N; Ibanes-Gutiérrez C; Vargas-Alarcón G; Martínez-Rodríguez N; Monroy-Muñoz IE; Valente-Acosta B; Pérez-Méndez O; Barrera-Ramírez R; Juárez-Cedillo T; Rodríguez Pérez JM
Gac Med Mex; 2013; 149(6):655-67. PubMed ID: 24276189
[TBL] [Abstract][Full Text] [Related]
10. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
[TBL] [Abstract][Full Text] [Related]
11. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome.
Derosa G; D'Angelo A; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; Cicero AF
Heart Vessels; 2007 Nov; 22(6):361-70. PubMed ID: 18043992
[TBL] [Abstract][Full Text] [Related]
12. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
13. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
